Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial.
about
Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation.Anti-Interferon Alpha Antibodies in Patients with High-Risk BCR/ABL-Negative Myeloproliferative Neoplasms Treated with Recombinant Human Interferon-α.Elimination half-lives of interleukin-6 and cytokine-induced neutrophil chemoattractant-1 synthesized in response to inflammatory stimulation in rats.Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN
P2860
Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Incidence, characterization, a ...... clerosis in the ADVANCE trial.
@en
Incidence, characterization, a ...... clerosis in the ADVANCE trial.
@nl
type
label
Incidence, characterization, a ...... clerosis in the ADVANCE trial.
@en
Incidence, characterization, a ...... clerosis in the ADVANCE trial.
@nl
prefLabel
Incidence, characterization, a ...... clerosis in the ADVANCE trial.
@en
Incidence, characterization, a ...... clerosis in the ADVANCE trial.
@nl
P2093
P2860
P356
P1476
Incidence, characterization, a ...... clerosis in the ADVANCE trial.
@en
P2093
Ali Seddighzadeh
Joleen T White
Mary Crossman
Meena Subramanyam
Robert A Bermel
Scott D Newsome
Serena Hung
P2860
P304
P356
10.1177/1756285616633967
P577
2016-03-10T00:00:00Z